What is a media fill test and why is it considered the ultimate proof of sterile manufacturing? The media fill — now more accurately called an Aseptic Process Simulation (APS) — is a complete simulation of the aseptic process in which the product is replaced with a microbiological growth medium. If every filled unit is clear at the end of incubation, the process has demonstrated its ability to maintain sterility; if even a single unit shows microbial growth, the test has failed. With the 2022 revision of EU GMP Annex 1, in force since August 2023, the APS is no longer a periodic box-ticking exercise: it has become a central pillar of the Contamination Control Strategy (CCS). This guide covers how the test works, what the regulation requires, and the mistakes inspectors challenge most often.
What the media fill (Aseptic Process Simulation) is
In a media fill, the aseptic process is run exactly as in production — same rooms, same equipment, same operators, same interventions — but instead of product, a sterile growth medium is filled, typically Tryptic Soy Broth (TSB), chosen for its ability to support a broad spectrum of microorganisms. The filled units are sealed, incubated and inspected: every turbid unit reveals a contamination event that, under real conditions, would have ended up in a product destined for a patient.
The terminology shift from "media fill" to "Aseptic Process Simulation" is not cosmetic. Annex 1 makes clear that the simulation must cover the entire aseptic process — from equipment preparation and assembly through to container closure — and not just the filling step. Real worst cases must be represented: maximum campaign duration, maximum number of operators present, shift changes, breaks, inherent and corrective interventions, simulated line stoppages and operator fatigue.
Do not confuse the media fill with the sterility test: the sterility test samples a batch of product that has already been manufactured, whereas the APS validates the process as a whole. The first is a quality control check on the outcome; the second is documented evidence that the way you manufacture is capable of assuring sterility over time.
What Annex 1 requires (paragraphs 9.32–9.49)
The 2022 revision of Annex 1 dedicates paragraphs 9.32 to 9.49 of Section 9 to the APS, with one guiding principle: the simulation must be designed on the basis of Quality Risk Management, starting from the risks identified in the CCS. There is no "standard" APS: the protocol must justify, risk by risk, the choices made — which interventions to simulate, which container sizes to use (normally the worst-case container/closure combination), what duration to cover, and how to represent production campaigns including start and end of campaign.
The logic also changes with the technology: isolators, RABS and manual processes carry different risks and therefore call for different APS designs. For processes with extensive manual interventions the bar is higher, because the operator is the main source of contamination.
Topics like this — Annex 1 requirements, sterility assurance, audit readiness — are the bread and butter of The Pragmatic GMP, GuideGxP's free weekly newsletter: one practical deep-dive a week, written for professionals in QA, QC and sterile manufacturing. Subscribe here.
Frequency, number of units and incubation
The fundamental numbers of the media fill are few and worth knowing by heart, because they are among the first questions in any inspection of a sterile facility:
| Aspect | Requirement |
|---|---|
| Initial validation | At least 3 consecutive satisfactory simulations, covering all working shifts |
| Periodic requalification | Approximately every 6 months for each aseptic process, filling line and shift |
| Number of units | Batches < 5,000 units: at least equal to batch size; larger batches: normally 5,000–10,000 units |
| Incubation | Minimum 14 days; a common scheme is 7 days at 20–25 °C followed by 7 days at 30–35 °C |
| Acceptance criterion | Zero contaminated units: any growth constitutes a failed APS |
On top of these comes personnel qualification: anyone performing aseptic operations must have participated in a successful APS before being authorized, and participation must be maintained over time — FDA's 2004 aseptic processing guidance expects each operator to participate at least once a year.
How the test is performed, step by step
- Protocol: risk-based definition of line, format, duration, interventions to simulate, number of units and acceptance criteria, with a documented rationale.
- Medium preparation: sterilization of the TSB and verification of its fertility (growth promotion test) with low-inoculum reference strains.
- Execution: filling under conditions representative of the worst case, with the planned interventions carried out by the operators actually involved in production and full environmental monitoring.
- Unit reconciliation: all filled units must be reconciled; rejects are acceptable only if foreseen and justified by the same SOPs that apply in routine production.
- Incubation and inspection: incubation for at least 14 days with 100% visual inspection of the units by qualified personnel.
- Final medium check: repetition of the growth promotion test at the end of incubation, to demonstrate the medium was still fertile.
Failed APS: what happens with one contaminated unit
On this point Annex 1 leaves no room for interpretation: the target is zero growth and a single contaminated unit is enough to declare the APS failed. The consequences are severe and must be managed with a procedure written before it is needed: a formal investigation with identification of the microorganism to species level, a root cause analysis extended to personnel, environment and utilities, an impact assessment of all batches produced since the last successful APS (with possible recall), corrective actions and, before resuming production, a revalidation that normally requires three consecutive successful simulations.
The most frequently cited mistakes in inspections are recurrent: simulated interventions less demanding than the real ones, unjustified unit rejects, unqualified incubators, visual inspection performed by untrained personnel, and APS runs performed under "ideal" conditions that do not represent routine production. An APS designed to be passed easily protects neither the patient nor the company: it is false assurance that inspectors recognize at first glance.
GuideGxP recommendation
Treat the APS as a project, not a deadline. Three practical tips: keep an up-to-date real-interventions/simulated-interventions matrix signed off by production and QA, so you can demonstrate in an audit that the simulation covers daily practice; plan the semi-annual windows per line and shift at least three months in advance, because a missed APS means a line that is no longer qualified; and write your failed-APS management procedure before you need it, including the criteria for assessing batches produced since the last successful test.
If you need to design, run or defend an APS in an inspection, the GuideGxP operational guide Aseptic Process Simulation (Media Fill): designing, executing and defending the APS under Annex 1 and FDA includes protocols, intervention matrices and ready-to-use templates aligned with Annex 1, FDA and PIC/S.
